ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P ASX 200
7,997.10
0.00%
S&P ASX All Technology
3,441.80
0.00%
Brent Oil
64.665
-2.06%
US Dollar vs AUD
1.55448
-0.81%
Bitcoin
94,636.29
0.94%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Sosandar Plc (SOS) Share Price

Sosandar Plc

Sosandar Plc (SOS)

Sostravelcom SpA
SOS Limited
6.00
0.00
(0.00%)
Closed 29 April 1:30AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
6.00
Bid
5.50
Offer
6.50
Volume
62,308
6.00 Day's Range 6.00
5.25 52 Week Range 12.25
Market Cap
14.894M
Previous Close
6.00
Open
6.00
Last Trade
50000
@
6.3
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
492,836
Shares Outstanding
248,226,513
Dividend Yield
-
PE Ratio
-35.29
Earnings Per Share (EPS)
-0
Revenue
46.28M
Net Profit
-423k

About Sosandar Plc

Sector
Apparel & Accessories, Nec
Industry
Apparel & Accessories, Nec
Website
www.sosandar.com
Headquarters
Cheshire, Gbr
Founded
-
Sosandar Plc is listed in the Apparel & Accessories sector of the London Stock Exchange with ticker SOS. The last closing price for Sosandar was 6p. Over the last year, Sosandar shares have traded in a share price range of 5.25p to 12.25p.

Sosandar currently has 248,226,513 shares in issue. The market capitalisation of Sosandar is £14.89 million. Sosandar has a price to earnings ratio (PE ratio) of -35.29.

Ask ADVFN Intelligence (AI)

SOS Latest News

More News

*Sosandar FY25 revenue GBP37.2m, up from GBP46.3m YoY

...
Alliance News
16 April 2025
SOS (0.00%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10066.2563193996DE
4-1.75-22.58064516137.757.955.254162036.78674489DE
12-0.6-9.090909090916.68.125.254928366.88687551DE
26-4-401010.55.255092947.723586DE
52-6.25-51.020408163312.2512.255.254453538.81271097DE
156-21.25-77.981651376127.2527.255.2543550015.94979972DE
260-4.5-42.857142857110.536.55.2549403918.44327272DE

SOS - Frequently Asked Questions (FAQ)

What is the current Sosandar share price?
The current share price of Sosandar is 6.00p
How many Sosandar shares are in issue?
Sosandar has 248,226,513 shares in issue
What is the market cap of Sosandar?
The market capitalisation of Sosandar is GBP 14.89M
What is the 1 year trading range for Sosandar share price?
Sosandar has traded in the range of 5.25p to 12.25p during the past year
What is the PE ratio of Sosandar?
The price to earnings ratio of Sosandar is -35.29
What is the cash to sales ratio of Sosandar?
The cash to sales ratio of Sosandar is 0.32
What is the reporting currency for Sosandar?
Sosandar reports financial results in GBP
What is the latest annual turnover for Sosandar?
The latest annual turnover of Sosandar is GBP 46.28M
What is the latest annual profit for Sosandar?
The latest annual profit of Sosandar is GBP -423k
What is the registered address of Sosandar?
The registered address for Sosandar is 40 WATER LANE, WILMSLOW, CHESHIRE, SK9 5AP
What is the Sosandar website address?
The website address for Sosandar is www.sosandar.com
Which industry sector does Sosandar operate in?
Sosandar operates in the APPAREL & ACCESSORIES, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VRSVersarien Plc
0.04p
(53.85%)
275.05M
TOMTomco Energy Plc
0.0525p
(50.00%)
70.56M
ENETEthernity Networks Ltd
0.0325p
(44.44%)
214.27M
MET1Metals One Plc
27.00p
(42.11%)
10.59M
AURRAurrigo International Plc
62.00p
(33.33%)
376.4k
NTQEnteq Technologies Plc
0.35p
(-30.00%)
10.04M
ARVArtemis Resources Limited
0.365p
(-27.00%)
14.16M
MTCMothercare Plc
2.00p
(-25.93%)
298.64k
CYANCyanconnode Holdings Plc
7.75p
(-23.27%)
4.12M
FDBKFeedback Plc
13.75p
(-21.43%)
625.81k
CHPCaledonian Holdings Plc
0.00475p
(11.76%)
5.68B
PREMPremier African Minerals Limited
0.0385p
(1.32%)
1.65B
SYMESupply@me Capital Plc
0.0034p
(-15.00%)
989.11M
EMEEmpyrean Energy Plc
0.0875p
(-18.60%)
436.4M
VRSVersarien Plc
0.04p
(53.85%)
275.05M

Discussion

View Full Feed
imafan imafan 2 minutes ago
Eeyore has spoken! AKA professed lying short. Real News: HUUUUGE ANNOUNCEMENTS of HUUUUGE ACCOMPLISHMENTS IMMINENT!!! WHALES LURKING!!!
HHSE
StockItOut StockItOut 3 minutes ago
Another SmartyPants/Quester lie, or you have a filing to support your assertion?
XERI
fuagf fuagf 3 minutes ago
LOL Figured that comment would grab you. 🙃 Qualification to mine would be, of course, unless they had firm numbers wrapped up with more security than Fort Knox. While fully appreciating the gravity you see in the situation, and though I've read little lately, still am guessing it's better t
glenn1919 glenn1919 3 minutes ago
CTMX..............................................a/h
CTMX
dia76ca dia76ca 4 minutes ago
"Blarcamesine and Anavex 3-71 are changing the paradigm for the treatment of neurodegenerative and neurodevelopmental diseases."
Nice summary georgejjl !
Paradigm shifts are very exciting but some folks see them before others!
The rest of this year will be pivotal.
2026 s
AVXL
Lykiri Lykiri 4 minutes ago
Actually, there’s a bit of confusion here. Under the old regulation, both positive and negative recommendations were referred to the CHM for review. However, the new regulation (effective after 3 April 2025) stipulates that only applications with serious concerns are now referred to the CHM. Therefo
NWBO
I-Glow I-Glow 5 minutes ago
And the Hindenburg report.- https://hindenburgresearch.com/mullen/.

Plus, TenKay was all over the preferred shares and the financials.

IG
MULN
boi568 boi568 5 minutes ago
Even if an ADL "odds ratio" claim could normally be considered disqualifying in lieu of a comparison of the means, it just seems to me irrelevant to the EMA here, since ADL itself is a not ready for prime time EMA endpoint in an early AD trial.
AVXL
dennisdave dennisdave 5 minutes ago
I agree with your points . However there were medicines last year which got approved by MHRA but NICE decided not to get them covered by NHS same day or so. Those companies would have been in discussions with NICE before MHRA approval . So not really sure it is absolutely comforting Ok interesting
NWBO
hedge_fun hedge_fun 6 minutes ago
That’s what I said, you’re smarter than……

the markets.

In your opinion of course!
TSLA
WarMachine WarMachine 6 minutes ago
I couldn't imagine making such a fool of myself every day on a public forum.
You don't need to imagine it. LOL
they are beyond clueless about what's really happening here
Explain, IN DETAIL, with PROOF to validate your claims, EXACTLY what is going on here. Or is it YOU who is
MONI
Uncle Monkey Uncle Monkey 6 minutes ago
wow! huge MAGA action today. FSR

hahaha
CBRF
Natural Trader Natural Trader 7 minutes ago
it does with high PT
exwannabe exwannabe 7 minutes ago
Impossible, they have to by law. They cant simply stop discussion because NWBO "might" get refusal.
I do not claim to know how the MHRA-NICE communications work.

But I do think I understand the NICE process well enough. They are at hold waiting for the evidence submission. Ever
NWBO
Truenorth2016 Truenorth2016 8 minutes ago
Any Dip Before News IMO is a Golden Opportunity Set-up!!!
CAVR
skitahoe skitahoe 9 minutes ago
There have been many bashers here saying that NICE wouldn't even speak to the company, and it would be next year or later before they would be able to treat patients with payment from the UK healthcare system. It seems like they're very wrong and the system may be ready for patients very shortly af
NWBO
dennisdave dennisdave 9 minutes ago
so it's your belief Linda dares not to disclose negative material news Ofcourse she will but I think they will probably do that when there is no more escape route IF there is bad news to report. The 10K left them no option had they prior to that received bad news so I am pretty sure they didn't rece
NWBO
manibiotech manibiotech 9 minutes ago
I agree with your points . However there were medicines last year which got approved by MHRA but NICE decided not to get them covered by NHS same day or so. Those companies would have been in discussions with NICE before MHRA approval . So not really sure it is absolutely comforting . Looks like the
NWBO
fwb fwb 9 minutes ago
You have issues,
find a woman
Let her HELP YOU get RIGHT... if you know what I mean
PLTR
I-Glow I-Glow 9 minutes ago
I believe there is a caveat to that provision as the company also has to be Deficienct in another listing requirement.

TK, can explain it much better as well as others.

IG
MULN
ddls ddls 9 minutes ago
4/28/25, Buy: 525,000, Neutral: 4,076,000, Sell: 11,275,500

One last day buy ask slap trade to make this junk look good.
BIEL
archilles archilles 9 minutes ago
Isn’t there a newly graduated law student recently passed the bar exam lawyer who will take on this case for experience for small pro bono fees. This should be a relatively easy to identify the bad guys and the victims. What we have here are the victim shareholders, who got ripped off, versus the
ENZC

Your Recent History

LSE
SOS
Sosandar
BIT
P10UN3
Bnp Paribas Issuance
NASDAQI
RTLSCNR
Benchmark Retail Real Es...
COIN
AROGBP
Arionum
USOTC
MDGC
MediaG3 (CE)
BIT
P1DPK2
BNP Paribas Issuance
LSE
0A1S
Dow
COIN
PNLUST
PNLToken
LSE
0NIQ
Sartorius
NASDAQ
XGN
Exagen
NASDAQ
FRME
First Merchants
LSE
GILS
Amundi Uk Gov
LSE
0JDP
Iron Mountain
USOTC
ASCBQ
Ascendia Brands (CE)
USOTC
SLSCF
Solasto (PK)
USOTC
BBAAY
Alibaba (PK)
Delayed Upgrade Clock
ADVFN Logo
Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads